Peripheral manifestations of nigrostriatal neurodegeneration in Parkinson's disease.

Advances in Modern Biomedicine

The urgent need for reliable biomarkers, early diagnosis, and multidisciplinary disease-modifying strategies for future therapeutic interventions is highlighted, with particular emphasis on challenges associated with bench-to-bedside translation.

Circulating biochemical signatures of neurodegeneration in Alzheimer's disease.

The blood-based biomarkers represent a transformative step toward early diagnosis, large-scale screening, and precision medicine in AD, with significant potential for the development of disease-modifying therapies.

Redefining Alzheimer's disease diagnostics in the age of blood-based biomarkers.

Research Progress on the Pathogenesis of Parkinson's Disease and the Neuroregulatory Mechanism of Deep Brain Stimulation Based on Animal Models

The core pathological features of Parkinson's disease (PD) are the loss of dopaminergic neurons in the compact part of the substantia nigra and the abnormal aggregation of α-synuclein; animal models can reproduce the pathological phenotype of this disease at multiple levels and serve as important tools for exploring it...

Parkinson’s Disease Dementia: Etiology, Mechanisms, Diagnosis, Management and Future Directions

Disease-modifying therapies remain investigational, but future directions include biological staging, precision phenotyping, synuclein-targeted immunotherapy, lysosomal enhancement, neuroinflammation modulation, digital biomarkers, and integrated trials across the Lewy body disease spectrum.

Neurofilament impairment in neurodegenerative diseases: pathogenesis, biomarkers and diagnostic values

Neurofilament (NF) proteins, as integral components of the neuronal cytoskeleton, are essential for maintaining axonal structure and function. Genetic defects, aberrant post-translational modifications, and co-aggregation with other pathogenic proteins can disrupt NF homeostasis, leading to axonal injury and neuronal d...